Several studies suggest that microangiopathy plays a crucial role in the pathogenesis of psoriasis. TNFalpha up-regulates the genetic transcription ofVEGF, a pro-angiogenetic cytokine over-expressed in psoriatic skin, which promotes micrangiopathic modifications in psoriatic plaque. Etanercept is a chimeric protein used in the treatment of psoriasis and other immunomediated disorders, which blocks inflammatory response by interfering in the binding ofTNF-alpha to its receptors. Starting from this data, we retain that Etanercept can improve microangiopathy in psoriatic skin by reducing the synthesis of pro-angiogenetic chemokine VEGF. The aims of the study are: to verify the effect of Etanercept on cutaneous en plaque capillaries in vivo using intra-vital videocapillaroscopy analysis, to evaluate the relation between the en plaque videocapillaroscopic pattern and the immunohistochemical cutaneous expression ofVEGF in psoriasis, and finally to correlate all these in data with clinical disease activity. Eighteen patients (10 male and 8 female, mean age 51, range 21-60) suffering from stable, en plaque type psoriasis, involving at least 10% of body surface area (BSA), and not responsive to conventional therapy were included in the study. All the enrolled patients received Etanercept 50mgltwice/week, subcutaneously, for 12 weeks, and were carefully followed up for clinical response with PASI score and DLQI index both before (To) and after 12 weeks (T 12 ) of treatment with Etanercept. A welldemarcated psoriatic plaque ofthe extensor surface of upper extremities was chosen to perform an intra-vital videocapillaroscopy analysis (IVCP), and a skin biopsy for immunohistochemical study both at To and T 12 in all the included patients, in order to evaluate the presence of microangiopathy and its modification after therapy. All the patients experienced a clinical improvement of cutaneous disease with a significant decrease of PASI score (p<0.000l) and DLQI level (p<0.0001), throughout the twelve weeks of treatment. On IVCP analysis, microangiopathy dramatically decreased (p<0.0001), this modification being significantly related with PASI and DLQI decrease at T 12 • Immunohistochemical expression of VEGF decreased significantly from Toto T I2 (p<O.OOOl), and was related with a reduction of psoriatic microangiopathy at T 12 • The results of our videocapillaroscopic and immunohistochemical investigation confirm that the therapeutic potentiality of Etanercept is based also on its capability to promote the regression of psoriatic microangiopathy. Moreover, according to these considerations, videocapillaroscopic evaluation of psoriatic plaque, both before and after treatment with Etancercept, may be a useful tool to objectively demonstrate its effect on microcirculation.
Several studies suggest that microangiopathy plays an important role in the pathogenesis of psoriasis and that VEGF, a pro-angiogenetic cytokine over-expressed in psoriatic skin, promotes the microangiopathic modifications in psoriatic plaque (1) (2) (3) (4) (5) (6) (7) (8) (9) .
The genetic transcription and tissue expression of VEGF are up-regulated by TNF-alpha (10) , which represents the specific target of Etanercept. Etanercept interferes with the binding of TNFalpha to specific receptors, (11) (12) (13) thus is actually used for the treatment of several diseases promoted and sustained by an over-expression of TNFalpha, including psoriasis. Starting from this data, we hypothesized that Etanercept can improve microangiopathy in psoriatic skin, by reducing the synthesis ofVEGF.
MATERIALS AND METHODS

Population
Eighteen patients (10 male and 8 female, mean age 51, range 21-60) suffering from stable, en plaque type psoriasis, involving at least 10% of body surface area (BSA), and not responsive to conventional therapy, were included into the study.
Exclusion criteria consisted in: erythrodermic and pustular psoriasis, and coexistence of diseases which may be associated with microangiopathy (diabetes mellitus, uncontrolled hypertension, collagenopathies).
The study was approved by the Marche Polytechnic University Ethical Committee.
All patients received Etanercept 50mg/twice/week, subcutaneously, for 12 weeks and were carefully followed-up for clinical response with PASI score and DLQI index both before (To) and after 12 weeks (T I2 ) of treatment with Etanercept.
Intra-vital videocapillaroscopy (Il/Ci')
A well-demarcated psoriatic plaque located on the extensor surface of upper extremities was chosen to perform an intra-vital videocapillaroscopy analysis (IVCP) both at To and T12 in all the included patients, in order to evaluate the presence of en plaque microangiopathy and its modification after therapy.
IVCP examination is an imaging technique that involves the direct visualization of skin capillaries using an optic contact probe microscope attached to a computerized video microscope (Fotofinder at magnification x60, x I00, x200).
In agreement with the classification of psoriatic microangiopathy provided by Trevisan et coil. (5) , we detected four different morphological patterns of capillary loops in lesional skin, and we named them according to their morphological videocapillaroscopic appearance: type I "treble clef capillaries", type II "hom capillaries", type III "clover leaf capillaries", type IV "bushy capillaries".
Ymmunohistochemistry
A cutaneous biopsy was performed at the same level both at To and T 12 , in order to evaluate the histological profile of cutaneous lesions, and all the modifications induced by the treatment. Skin biopsy samples from 10 healthy donors and from the 18 patients were fixed in 10% buffered formalin for 24 h and were paraffin-embedded. Tissue sections 4-5 urn thick were processed by heating sections in a microwave at 98°C in a citrate buffer pH 6 solution for 40 minutes for antigen retrieval. Endogeneous peroxidase activity was blocked by 3% hydrogen peroxide incubation for 10 minutes before adding the primary antibody anti-VEGF (Clone C-I, Santa Cruz Biotechnology), dilution I :250, with an incubation at 4°C overnight. As revelation system we used EnVision system ® (DAKO) / HRP and diaminobenzidine (DAB) as chromogen. Finally, the sections were counterstained with hematoxylin, and coverslipped with Paramount.
The immunostained sections were then examined under a light microscope by a pathologist who counted the number of cells immunoreactive for VEGF in consecutive fields at 250x magnification within a calculated area. For each sample the amount of cells immunoreactive for VEGF, including the epidermal keratinocytes, the fibroblasts and inflammatory cells of the dermis, were expressed as density per mm-.
Statistical analysis
A non-parametrical analysis of variance for repeated measurements was used to evaluate PASI score, DLQI level, total amount and proportion among different types of microangiopathic capillaries, immunohistochemical expression of VEGF, and their relation with disease activity, across the points-time.
Comparisons between baseline and T I 2 measurements were performed to search for any significant differences across the time.
RESULTS
Clinical response
All the patients experienced a clinical improvement of cutaneous lesions with a significant decrease of PASI and DLQI mean value from 18.382+/-4.381 to 5.831+/-1.742 and from 11.164+/ 
IVCP analysis
IVCP evaluation of psoriatic lesional skin at To showed the presence of diffuse microangiopathy by means of uniformly arranged , tortuous and enlarged capillary loops, (Fig. la, lc) , and a great reduction of them after twelve weeks of therapy with Etanercept ( Fig. 1b, 1d ).
The four morphological variants of capillary loops detected in lesional skin, both at Toand T 12 , are reported in Table I and Fig. 2. In uninvolved psoriatic skin, the vessels were not detectable by IVCP.
The total amount of tortuous and enlarged capillaries per field at 60x magnification dramatically decreased from a mean value of 120.444+/-24.471 at To to a mean value of 16.111+/-21.534 at T I2 (p<O.OOl), whereas the proportion among the different patterns of capillary loops remained unchanged (Table I) .
The improvement of microangiopathy was significantly related with PASI (Fig. 3) , and DLQI score decrease at T I2 •
Histological and immunohistochemical analysis
Before therapy the epidermal keratinocytes of all layers, the inflammatory cells, and the endothelial cells in the dermis showed a diffuse cytoplasmic staining. The epidermal pattern of distribution of VEGF immunoreactivity tended to change from diffuse to basal after twelve weeks of therapy ( Fig. 4) , moreover, the overall density of VEGF immunoreactive cells significantly decreased from a baseline value of 19.2777+/-7.193 per mm' to 7.888+/-6.434 per mm' (p<O.OOl) after twelve weeks of treatment, and it was related to the reduction of dystrophic capillaries at T I2 (Fig.5 ).
DISCUSSION
Psoriasis is a chronic dermatosis whose etiopathogenesis still remains unclear. However, several studies have extensively evaluated the crucial role of microcirculation in the development of disease, by means of intra-vital videocapillaroscopy (1-5), and one of our previous immunohistochemical analysis focused on the importance of VEGF in increasing angiogenesis occurring in psoriasis (6) .
As its name suggests, VEGF stimulates vascular endothelial cell growth, survival, and proliferation by binding with two related receptors located on the endothelial cell membrane, named VEGF receptor-I (VEGFR-l) and VEGFR-2 (6) .
The interaction between the VEGF and VEGFR family of receptors, particularly VEGFR-2, initiates a signalling cascade that impacts the survival proliferation and migration of endothelial cells, leading to angiogenesis in cutaneous psoriatic lesions (6) . Cellular synthesis and tissutal expression ofVEGF are up-regulated from TNF-alpha (10), and endothelial cells -the putative target -also release VEGF, both constitutively and in response to TNFalpha, leading to an autocrine pathway that amplifies the angiogenetic effect ofVEGF (14) .
Etanercept is a human TNF -alpha receptor, made from the fusion of 2 naturally-occurring TNF-alpha receptors, that binds to TNF-alpha with great affinity. This binding makes the TNF-alpha biologically inactive, potentially resulting in a reduction of VEGF expression.
Our investigation confirmed that psonatIc microvessels are elongated, widened and convoluted in clinically involved skin , and four morphological patterns ofcapillary loops may be distinguished (type I-IV) by means of intra-vital videocapillaroscopy (5) .
The provided classification implicitly reflects a grading in morphological severity of microangiopathic capillary loops, even if it is impossible to establish with certainty a progression 12 . . of microangiopathic capillaries from grade I to grade IV, also because the four variants of capillary loops usually co-exist within the same cutaneous lesion at the time of the first diagnosis.. In our series, Etanercept administration led to a significant regression in the total number of tortuous and enlarged capillaries after twelve weeks of therapy, whereas the proportion among different loops' morphological patterns remained unchanged at videocapillaroscopic level; these data seems to suggest an "all-null" effect of Etancercept on microangiopathy in the course of psoriasis.
The amelioration of microangiopathy was evident also at the histological level: Etanercept administration induced a reduction of VEGF immunohistochemical staining intensity, running parallel to the regression of micro angiopathy, and also favoured the restoration of a gradient typical of non-psoriatic skin, with major VEGF expression in the lower layers of epidermis.
The improvement of micro angiopathy was strictly related with clinical healing in all psoriatic patients, supporting that microangiopathy may be a fundamental pathogenetic promoter of cutaneous manifestations of psoriasis.
Controversy exists whether the "primum movens" in psoriasis is primarily epidermal or dermal (vascular); Hem et colI. have recently demonstrated that blood vessels must, at least in part, play an important, but probably secondary role in the pathogenesis of cutaneous lesions in the course of psoriasis (1).
However, it has already been elucidated that microangiopathic features usually appear before any other dermal or epidermal modifications in psoriatic skin, as demonstrated by the fact that morphological changes in perilesional skin capillaries usually occur at a greater distance from the edge of a plaque than changes in keratinocytes (15) .
Moreover, the appearance of dermal microangiopathy in the course of psoriasis generally anticipates a clinical relapse (7) , and a treatment promoting a microangiopathy regression leads to a more stable clinical healing from cutaneous manifestation of psoriasis, with a prolongation of disease-free survival (16) .
The results of our videocapillaroscopic and immunohistochemical investigation seem to confirm that the well-known therapeutic potentiality of Etanercept is based also on its capability to promote the regression of psoriatic microangiopathy. Moreover, according to these considerations, videocapillaroscopic evaluation of psoriatic plaque, both before and after treatment with Etancercept, may be a useful tool to objectively demonstrate its effect on microcirculation.
The mechanisms inducing cutaneous microcirculatory changes during psoriasis are not completely elucidated, but there is considerable evidence that several proangiogenetic factors, other than VEGF, such as transforming growth factor a (17) , interleukin-8 (18), plated-derivate endothelial cell growth factor (19) , are overproduced in psoriatic epidermidis, thus larger clinical, videocapillaroscopic, and immunohistochemical studies, including the analyses of all these cytokines simultaneously implicated in psoriatic angiogenesis, are required to better elucidate the pathways mediated by Etanercept in the control of psoriatic microangiopathy.
